Although high-risk MM patients benefit from CD38 antibodies, the poor-risk cytogenetic abnormalities might have a negative impact on clinical outcome in patients across treatments, and further research is needed in these populations. The gene discussed is CD38; the disease is Miyoshi myopathy.